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Protein aggregation remains a major area of focus in the production of monoclonal antibodies. Improving the
intrinsic properties of antibodies can improve manufacturability, attrition rates, safety, formulation, titers,
immunogenicity, and solubility. Here, we explore the potential of predicting and reducing the aggregation
propensity of monoclonal antibodies, based on the identification of aggregation-prone regions and their
contribution to the thermodynamic stability of the protein. Although aggregation-prone regions are thought to
occur in the antigen binding region to drive hydrophobic binding with antigen, we were able to rationally design
variants that display a marked decrease in aggregation propensity while retaining antigen binding through the
introduction of artificial aggregation gatekeeper residues. The reduction in aggregation propensity was
accompanied by an increase in expression titer, showing that reducing protein aggregation is beneficial
throughout the development process. The data presented show that this approach can significantly reduce
liabilities in novel therapeutic antibodies and proteins, leading to a more efficient path to clinical studies.
© 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Protein particles are assemblies built up of native
and/or denatured proteins [1] that generally have a
negative impact on manufacturability, stability, safety,
titers, immunogenicity, and solubility of biologics in
general [2–6]. Here, we investigate the impact of
β-aggregation-prone sequences on protein particle
formation and assess our ability to predict and
suppress antibody particle formation based on this
structural mechanism alone. β-aggregation is the
process of association of proteins, predominantly
through the formation of intermolecular beta-sheetuthor(s). Published by Elsevier Ltd. This is
rg/licenses/by/4.0/).structures by short aggregation-prone regions (APRs)
of the polypeptide sequence [7]. Despite the fact that
APRs are mostly hydrophobic in nature, they require
other key properties such as a high β-sheet propensity
and a low net charge. Common methods of aggrega-
tion prediction are geared toward the identification of
APRs in the primary sequence [2–5,8,9]. These
prediction methods establish the theoretical aggrega-
tion potential of the protein in the unfolded state, called
the “intrinsic aggregation propensity”. To nucleate
aggregation, an APR must be solvent exposed in
order to form stable interactions with other like
sequences. However, in most globular proteins,an open access article under the CC BY license
J Mol Biol (2017) 429, 1244–1261
1245Aggregation of Monoclonal Antibodiesthese APRs are buried inside the hydrophobic core of
the native structure, where they are prevented from
triggering aggregation by the thermodynamic stability
of the protein [7,10,11]. Noteworthy exceptions are●
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(e)APRs occurring at exposed sites of functional
importance such as protein–protein interaction inter-
faces [12–15]: here, the functional requirements of the
site appear to lead to the emergence of APRs that can
be problematic when the protein is not engaged in
functional interactions. The effective aggregation of
a protein is thus dependent on the population of
aggregation-compatible conformations in which the
APRs are exposed. The interplay of physicochemical
parameters such as protein and ion concentrations,
pH, and temperature contributes to determine the
concentration of aggregation-prone conformers in a
protein solution. Therefore, the challenge for relatively
large and thermodynamically stable proteins like
antibodies is identifying sequences that will aggregate
under native conditions. The solution to this challenge
lies in the distinction between APRs that are thermo-
dynamically protected by folding and those that occur
in aggregation-competent conformations that can
form without major unfolding transitions (Fig. 1a).
The latter regions would be the critical APRs that
determine aggregation propensity under native con-
ditions. We previously demonstrated for protective
antigen and alpha-galactosidase that mutations in
these critical APRs dramatically reduce the overall
aggregation rate of the protein and increase the
amount of soluble produced protein in mammalian
cells. These mutations introduced the so-called
suppressing gatekeeper residues that oppress ag-
gregation locally [16]. Here, we investigated if the
approach is transferable to the engineering of
monoclonal antibodies, which is in itself non-trivial
given the difference in architecture and size between
antibodies and the previously studied cases. More-
over, we also wanted to test if the method would allow
the sorting of aggregation-prone antibodies from less
aggregation-prone ones, which would be extremely
valuable in prioritizing lead candidates for therapeutic
applications early during development.Fig. 1. In silico analysis of aggregation propensity in
antibody crystal structures. (a) Schematic representation
of possible locations of APRs in monoclonal antibodies.
APRs in CDRs would be more problematic than APRs
buried in the immunoglobulin fold. (b) Stretch-plots:
representation of aggregation propensity and local stability
of APRs. Problems increase toward the top right of the plot;
ideally, APRs would be located in the bottom left.
(c) Density plot of all APRs located in the FR of over 2000
antibody structures from the abYsis database [24].
(d) Density plot of aggregation propensity and local stability
of APRs in globular protein structures. The analysis is based
on a set of 2650 high quality structures (R-factor of b0.20
and resolution of b1.9, with 30% sequence identity) of
globular proteins generated using the Whatif software suite
[25]. (e) Density plot of all APRsoverlappingwithCDRsof all
antibody structure from the abYsis database. Cyan dots:
APRs overlapping with CDRs of the 11 model antibodies
used in the study.
1246 Aggregation of Monoclonal AntibodiesOur publicly available web-based tool† [17] as-
sumes that the distinction between a structural and a
critical APR is largely determined by the local
thermodynamic stability of the region containing the
APR. A structural APR contributes to protein stability
and is hence only available to trigger aggregation
upon denaturation, whereas a critical APR can trigger
aggregation under native conditions due to local
structural fluctuations. To determine thermodynamic
stability, we used here the empirical force field FoldX
[18]. FoldX estimates the free energy of folding of
protein structure by combining the local contributions
of all residues, and thus, it is well suited to evaluate
local stability (here called ΔGcontrib, in kcal/mol). To
detect the presence of APRs, we used the statistical
thermodynamic algorithm TANGO [19]. TANGO
calculates the intrinsic aggregation propensity of
APRs as a Boltzmann distribution with competing
secondary structural tendencies such as α-helical or
β-hairpin structure. The benefit of this implementation
is that TANGO predicts APRs [20] with well-defined
sequence boundaries, that is, with a clear-cut
separation between the APR and the surrounding
residues. In addition, and of particular interest for our
current purpose of identifying critical APRs, TANGO
achieves high specificity and thus predicts few
false-positive APRs [8]. Several other software
packages were developed to help find aggregation
hotspots in 3D structures [21–23]. As none of these
methods consider both intrinsic β-aggregation poten-
tial and explicit all-atom thermodynamic stability
calculations simultaneously, a force field such as
FoldX, or an alternative, needs to be combinedwith an
APR prediction method to obtain a complete method.Table 1. Antibody test set
Antibody Antigen PDB1 TANGO ΔG
corrected
TANGO
Net
charge
mAb1 unknown 3kyk[52] 2314 941 2
mAb2 VEGF 2fjf[37] 1908 377 3
mAb3 HIV 1hzh[53] 1131 71 10
mAb4 MHCI 3hae[54] 1621 51 3
mAb5 EGFR 3b2u[55] 2269 321 3
mAb6 GP41 1tzg[56] 1064 53 9
mAb7 GP41 3mac[57] 2042 681 −1
mAb8 HIV-UG29 2b0s[58] 1639 50 −3
mAb9 DNA 1dfb[59] 680 93 5
mAb10 TNF 1ad9[60] 695 71 3
mAb11 CD4 2adg[61] 771 4 −6
1 PDB IDs of crystal structure of the antibody itself or the
YASARA homology modeling template (underlined).Results
Visualization
To easily visualize the aggregation potential of an
antibody in function of both its intrinsic aggregation
propensity and thermodynamic stability, we developed
the so-called “Stretch-plot” (Fig. 1b). In a Stretch-plot,
eachAPR is represented by a single point, of which the
ordinate is determined by the local aggregation
propensity of the sequence segment (summed
TANGO, 5–100 per residue) and the abscissa by its
contribution to the free energy of folding (ΔGcontrib). In
theory, APRs in the top right corner are “critical” since
they occur in less stable regions of the protein and
display higher intrinsic aggregation propensities. To
analyze the relationship between intrinsic aggregation
propensity and the local thermodynamic stability of
antibody structures, we analyzed over 2000 antibody
structures from the abYsis database [24]. For each of
these antibodies, we performed a stretch-plot analysis
by determining their APRs and their contribution tolocal thermodynamic stability. Finally, we combined the
stretch-plots of all 2104 antibodies as heat maps (Fig.
1c and e). The analysis clearly revealed that APRs in
the framework region (FR) are, in large majority,
thermodynamically stable and therefore well protected
from aggregation (Fig. 1c). In fact, the stretch-plot
distribution of antibody FRs is very similar to the
stretch-plot distribution obtained for a representative
collection of globular proteins with various structural
topologies (Fig. 1d, based on a representative set of
high quality globular protein structures [25]). This
similarity is in stark contrast to the stretch-plot
distribution obtained for the complementarity-determin-
ing regions (CDRs) of the N2000 abYsis antibody
structures (Fig. 1e). APRswithin CDRs display amuch
broader distribution of thermodynamic protection, and
a significant proportion of these possess both high
intrinsic aggregation propensity (TANGO) and low
thermodynamic stability (FoldX), which would render
them aggregation competent under near-native condi-
tions. To investigate whether the results were suscep-
tible to redundancy, we filtered with different sequence
identity cutoffs, which did not have a profound effect on
the overall distribution of the plots (Supplementary Fig.
1). The stretch-plot distribution of FRs is consistentwith
the notion that these sequences have been evolution-
arily selected to minimize the occurrence of critical
APRs rather than contain strongly stabilizing APRs in
the hydrophobic core regions of their structure. On the
other hand, CDRs are selected ad hoc for antigen
binding and clearly explore more critical regions of the
stretch-plot. The stretch-plot distribution of CDRs
therefore indicates the emergence of potentially
problematic APRs in CDRs as a result of paratope
selection [3]. Indeed, analyses of antibody–antigen
complexeshave confirmed that aromatic residues (Tyr,
Trp, and Phe), which are substantially enriched in
APRs, are also considerably enriched in antibody
paratopes [26,27]. Interestingly, this is seen throughout
protein–protein interaction sites [28], independent of
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Fig. 2. Stretch-plots and schematic representation of the structure of the Fab fragment of the 11 model antibodies used
in this study. (a–k) Blue: APRs located in FR of the antibody. Red and green: APRs overlapping with CDRs in the heavy
chain (H) or the light chain (L), respectively. Numbers represent CDR number (Chothia numbering) with which the
respective APR is overlapping. Colors in structures: yellow: low scoring APR, red: high scoring APR.
1247Aggregation of Monoclonal Antibodiesfold or family. This raises the question as towhat extent
sequences can be selected to perform specific high
affinity binding without facilitating the formation of
associated APRs. The overlap between the physico-chemical parameters determining the paratopes
and those determining the APRs also underlines the
importance of highly specific APR predictions to avoid
the exclusion of false-positive “critical” antibodies. As
1248 Aggregation of Monoclonal Antibodiesaggregation is a concentration-dependent process,
critical APRs are expected to be most challenging
under conditions of high protein concentration, which30 40 50 60 70 80 90
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False positive rateoccurs not only in therapeutic formulations but also, for
example, in producer cells during recombinant
expression.
1249Aggregation of Monoclonal AntibodiesTest set composition and scoring function
To evaluate the impact of critical CDR-related
APRs on the antibody's solubility and aggregation
propensity, we decided to study the in vitro aggre-
gation of a set of 11 publicly known antibody
sequences (mAb1 to mAb11; Table 1). To compose
this set, all available human sequences from the
abYsis database were acquired and properties like
charge distribution, hydrophobicity, statistical se-
quence scores [29], CDR-specific properties, and
aggregation tendency (PASTA [30]) were computed.
For each of these properties, a distribution was
obtained and antibodies were selected that were
extreme in at least one property and had an X-ray
structure or a close homology modeling template
available. Exceptions were mAb5, which scored
average in all distributions, and mAb9 and mAb10
that were randomly selected for not having an X-ray
structure available at that time. The selected
antibodies contained APRs in their CDRs that span
the majority of the data in the density plot analysis
(Fig. 1e, cyan points correspond to the individual
CDR APRs from the test cases). Moreover, the
antibodies displayed a high diversity of stretch-plot
profiles, suggesting that some are more aggrega-
tion-prone than others (Fig. 2). Four of the antibodies
show APRs in their CDRs in the problematic region
of the plot, namely mAbs 1, 2, 5, and 7. Interestingly,
mAb9 does not conform to the general trend of Fig. 1
and has an APR in its FR of low thermodynamic
stability. The other plots (mAbs 3, 4, 6, 8, 10, and 11)
show no obvious problems.
To extract critical APRs from the stretch-plot of each
antibody and represent these by a single metric, we
developed a simple integrative scoring function. A
correctedTANGOscore for eachAPRwasdevised by
cutting off the ΔGcontrib at −5 and +5 kcal/mol and by
normalizing this value between 0 and 1 (0 being a
thermodynamically stable APR, 1 being an unstable
APR). Multiplying this value with the TANGO score
allows the mitigation of stable APRs in a way that the
total score is dominated by the contribution of critical
APRs. We named this scoring scheme “SolubisFig. 3. Characterization and scoring of the 11 model a
barycentric mean (BCM) of the fluorescence emission spect
Curves were used to derive the melting temperatures (Tm). (b
measured simultaneously with the data in (a). The aggregatio
plot of the melting points and aggregation onset temperatures
CHO DG44 cells measured at 0.7 mg/mL. mAb numbers are in
difference between the Tm and the Tagg (ΔTmTagg) for the teste
numbers are indicated. (e) Distribution of Solubis score ove
SL50K_FH101P. (f) Stretch-plot summarizing the aggregation
TANGO in 27 FDA-approved monoclonal antibodies. Blue: AP
overlapping with CDRs in the heavy chain (H) or the light chain (
numbering) with which the respective APR is overlapping. (g)
scoring function, TANGO, and the number of APRs to classi
structure or homology model built using one template (Table 1
using the results from different homology modeling approachescore” and set out to compare it to experimental
data obtained using our set of 11 antibodies. Wewere
not able to produce mAb1 from stably transfected
CHO DG44 cells, and mAb6 was found to fragment.
We experimentally determined thermal protein unfold-
ing and aggregation of all remaining antibodies.
Protein unfolding was monitored by intrinsic fluores-
cence (Fig. 3a) while simultaneously detecting aggre-
gation using right angle light scattering (RALS;
Fig. 3b) [31,32], yielding melting (Tm) and aggregation
onset (Tagg) temperatures, respectively. Substantial
aggregation of mAb7 prior to the analysis prevented
us from performing this analysis for mAb7. A plot ofTm
versus Tagg for the remaining antibodies (Fig. 3c)
shows that some of the tested antibodies aggregated
from the native conformation, that is, prior to the global
unfolding transition (Tagg b Tm), while for other anti-
bodies, aggregation onset only occurs upon global
unfolding (Tagg = Tm). This leads to the suggestion
that their exposed APRs play a major role in
aggregation. Importantly, no antibody resists aggre-
gation past the global unfolding transition, consistent
with the exposure of the APRs that are found in the
stable regions of all antibodies of the set (the antibody
with the lowest total number of APRs in this set has
four). Asmentioned above, the stretch-plot analysis in
Fig. 2 predicted antibodies 1, 2, 5, 7, and 9 to have
APRs in unstable regions of the structure, that is, to be
aggregation-prone under native conditions. Of these,
mAb1 could not be produced; mAb7 aggregated prior
to any analysis; and mAbs 2, 5, and 9 displayed the
largest difference between the Tm and Tagg values
(18.9 °C, 8.5 °C, and 7.6 °C, respectively). In con-
trast, among the antibodies with no obvious problem-
atic APRs, mAb6 displayed fragmentation during
production and had to be discarded, and mAbs 4,
11, and 10 showed a difference between Tm and Tagg
of less than 1 degree, whereas antibodies 3 and 8 had
intermediate values (4.6 °C and 2.8 °C, respectively).
Based on these observations, there seems to be a
clear trend toward earlier aggregation onset for the
antibodieswith critical APRs in their stretch-plots. This
can also be seen from the plot of Solubis score versus
the difference between Tm and Tagg, again showingntibodies. (a) Temperature-dependent evolution of the
rum of three representative antibodies from our test set.
) Temperature-dependent evolution of the RALS intensity
n onset temperature Tagg is derived from these data. (c) A
of all the test antibodies obtained from stably transfected
dicated. (d) Correlation between the Solubis score and the
d antibodies. (Pearson's correlation = 0.89, p b 0.02). mAb
r the different datasets. 1: WT, 2: FH101P, 3: SL50K, 4:
propensity and local stability of all APRs identified using
Rs located in the FR of the antibody. Red and green: APRs
L), respectively. Numbers represent CDR number (Chothia
Receiver operator curve showing the ability of the Solubis
fy the WT antibodies structures, based on original crystal
). (h) Receiver operator curve similar to (g) but calculated
s.
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1251Aggregation of Monoclonal Antibodiesthat low-scoring antibodies tend to have smallTm‐Tagg
differences (Fig. 3d). Although the size of our current
dataset precludes deriving firm conclusions on the
general applicability of the scoring method, these
results do suggest that the method allows
the identification of problematic sequences that can
drive antibody aggregation under native conditions.
In summary, TANGO identified between 4 and 10
APRs in these antibodies, which Solubis reduces
to 0, 1, or 2 APRs that are critical for native state
aggregation.
For this reason, we compared the Solubis scores of
the abYsis database to those of the antibodies
currently approved for human therapy by the US
Food and Drug Administration (FDA), for which we
could find sufficient structural data (27 sequences;
Fig. 3e and f). The plot depicts a Solubis score ranging
from 0 to 2500 for the abYsis database, compared to a
range of 0 to 685 for the FDA-approved sequences.
Less than 15% of the FDA-approved sequences score
above 300, a score that in our dataset was clearly
associated with aggregation. The fact that FDA-
approved antibodies are, according to our scoring,
not completely devoid of exposed aggregation-prone
sequences could suggest that our scoring is too
stringent. However, the FDA-approved antibodies
are formulated such that product stability is opti-
mized and aggregation minimized, while our test set
of nine mAbs was prepared in aqueous solution
without any stabilizing agents. The fact that moder-
ately aggregation-prone antibodies can meet safety
and efficacy requirements indicates that the selec-
tion of antibodies can be especially improved toward
favorable chemistry, manufacturing, and control
properties.
Robustness
Structure-based scoring functions are dependent on
the quality and accuracy of a crystal structure or a
suitable homology model. During early development,
crystal structures are unavailable in most of the cases.
However, a reliable homologymodel canalso serve as
a structural basis. Structure quality and accuracy are a
prerequisite, since the scoring relies on the calculation
of ΔGcontrib by FoldX. As this value is used to correct
the raw TANGO score, it thus has a profound effect on
the Solubis score. Despite the fact that there is a high
degree of structural conservation in the antibody
scaffold, a particular problem with explicit all-atom
force field calculations is that they are very sensitive toFig. 4. Design of APR disrupting mutations. (a) Stretch-plo
(b) Crystal structure of the variable domain of mAb2 with the AP
mAb2 with mutation effects on aggregation propensity and s
Crystal structure of mAb2 in complex with VEGF. Gray: mAb2
chain. Red: FH101, blue: Tryptophan located close to FH101, g
Zoom on the APR in the light chain. Magenta: SL50 and SL5
were made using YASARA Structure.relatively small errors in atomic coordinates. Thus, in
order to assess the impact of the modeling algorithm
on the scoring of the test set, wewanted to analyze the
impact of different methods to build the homology
models on our predictions. Hence, we used the
software programs YASARA [35] and MOE [36]. For
MOE, we prepared model structures with and without
an additional energy minimization step.
To allow for easy comparison between these
different models, we required a method to assess
the performance of our scoring function in classifying
aggregation-prone from soluble antibodies. To this
end, we discarded mAbs 1 and 6 from the analysis
and divided the remaining sequences into low and
high aggregation-prone. Since the size of our dataset
is too small to unequivocally resolve the twilight zone,
we arbitrarily placed the cutoff in Tm‐Tagg at 5 °C and
included mAb7 in the high aggregation-prone class.
Although this is obviously flattering for our approach,
this classification does allow us to easily detect a
negative impact of modeling methods on the predic-
tion success. Prediction performance of a classifica-
tion task can be visualized by a receiver operator
curve, which plots for each cutoff value of our Solubis
scoring function for critical APRs the fraction of correct
predictions versus the fraction of false-positive pre-
dictions (Fig. 3g). A random scoring function will
typically showawrong prediction for every correct one
made, and hence, its trace will lie near the diagonal. In
contrast, theSolubis score calculated from the original
structures lies on the curve through the upper left hand
corner of the plot, which means that the function can
flag the aggregation-prone antibodies in this small set
with the highest sensitivity (zero false-negative rate)
and high specificity (zero false-positive rate). In this
set, where we know which antibody is aggregation-
prone and classified it as such, the Solubis score
clearly outperforms simpler scoring schemes, such as
the total raw TANGO score or the number of APRs
identified by TANGO in the sequence. For complete-
ness, the Matthews correlation coefficient was 0.83,
and the area under curve was 0.93 for the YASARA
models and the MOE models with an additional
energy minimization step. Although there are some
differences between the scores obtained with each
method, the overall scoring remains very similar for all
antibodies with minimal impact on the prediction
performance, which is apparent from comparing the
receiver operator curves (Fig. 3h) of the different
modeling methods. This result shows that the
accuracy of state-of-the-art modeling engines allowst of mAb2; critical APRs are highlighted with red circles.
Rs highlighted. (c–d) MASS plots of the two critical APRs in
tability. Chosen mutations are highlighted in red. (e) Left:
, green: VEGF. Top right: Zoom on the APR in the heavy
reen: VEGFwith molecular surface displayed. Bottom right:
2, green: VEGF with molecular surface displayed. Images
1252 Aggregation of Monoclonal Antibodiesthe identification of critical APRs with similar
confidence.
Reducing aggregation by mutational APR
suppression
To further demonstrate the relevance of critical
APRs, we decided to employ the same computational
approach to select mutations that are predicted to
suppress APRs and to study their effect on antibody
production and aggregation. For this purpose, we
focused on mAb2 {Protein Data Bank (PDB) ID 2FJF
[33]}, which has a Solubis score of 407 and displays
pronounced protein aggregation under native condi-
tions, but the protein can still be expressed and
purified with reasonable yield. Indeed, the low Tagg
and large Tagg‐Tm gap of mAb2 (Fig. 3c) indicates this
antibody is particularly prone to aggregation from the
native state. Previouswork showed that a decrease of
aggregation propensity can be achieved by the
introduction of specific residues that oppose aggre-
gation, called aggregation gatekeepers [10,16,34].
These residues are either charged residues (Aspar-
tate, Glutamate, Arginine, or Lysine) or a Proline
residue, which strongly disfavors a β-strand confor-
mation. The stretch-plot of mAb2 reveals the identity
of two critical APRs located in CDR L2 and H3,
respectively (Figs. 2b and 4a and b). To identify
mutations that reduce the intrinsic aggregation pro-
pensity of these APRs while not decreasing their
contribution to the thermodynamic stability of the
antibody, we calculated the effect on the aggregation
propensity and protein stability of every mutation of
APR residues to a gatekeeper (i.e., five mutations per
position in the APR) and generated the so-called
mutant aggregation and stability spectrum (MASS)
plots [35] (Fig. 4c and d). In a MASS plot, each
mutation is represented as a point of which the
ordinate is determined by the change in intrinsic
aggregation propensity (TANGO) associated with the
mutation and the abscissa byΔΔG, that is, the change
in thermodynamic stability (FoldX). Using this ap-
proach, we identified and selected mutations that
were predicted to maximally reduce the aggregation
propensity of the critical APRs in the CDRs of mAb2
with the minimal unfavorable effect on the stability of
the protein. From the 55 possible mutations in L2, we
selected SL50K, SL52R, and SL50D for further
evaluation, and from the 65 calculated mutations in
H3,wepickedFH101PandVH100R (Fig. 4c, d, ande).
These mutations were predicted to render the APR
less aggregation-prone while not destabilizing the
protein too much, both locally and globally.
Improving colloidal stability through net charge
increases
Given the clear overlap between antigen binding
determinants and aggregation, we decided tosupplement the mutations that directly disrupt the
critical APRs by introducing suppressing gate-
keepers with mutations that act on the global net
charge of the proteins. Although this would not
eliminate the intrinsic aggregation potential of the
molecules, it would at least increase their colloidal
stability and hence reduce the initial association
required to initiate protein aggregation [36]. In
addition, APR disruption could display an interplay
with the net charge, as was observed in the
engineering of protective antigen [16], where we
noticed that the gatekeeper that increased the net
charge of the protein also performed best at reducing
aggregation. Moreover, for green fluorescent pro-
tein, it was previously shown that extreme super-
charging is effective at suppressing aggregation, but
this is probably not an option for therapeutic
molecules due to immunogenicity considerations
[36]. As it is known that heavy chain CDR 3 is often
critical for antigen binding, we figured that direct APR
disruption would most likely impact binding affinity.
Therefore, we set out to test alternative mutations
that act by supercharging the heavy chain. To this
end, we used FoldX to calculate the ΔΔG value of
each mutation that increased the net charge of the
heavy chain outside the CDRs, which, in the case of
the mAb2 heavy chain, is positive (+2). This yielded
627 potential mutations (Fig. 5a), from which we
selected 2 additional mutations in the heavy chain,
namely SH21R (ΔΔG = −1.2 kcal/mol) and SH85R
(ΔΔG = −1.2 kcal/mol; Fig. 5a and b). These muta-
tions were combined with the light chain APR
disrupting mutations SL50K and SL50R, in order to
see if the net charge increase could take the role of
APR disruption in the heavy chain. Moreover, we
also added the net charge mutations to the
combination of heavy chain and light chain APR
disruptors, giving rise to the set of mutations shown
in Table 2.
Effect of mutation on titer and aggregation
The mutants selected for the analysis (listed in
Table 2) were recombinantly produced and purified
from transiently transfected CHO K1 cells alongside
wild-type mAb2. Comparison of the intrinsic fluores-
cence emission and CD spectra of the mutant and
wild-type confirmed that the mutations did not cause
major alterations in the overall structure of the antibody
(Fig. 6a–c). In contrast, we observed major improve-
ments in the aggregation onset temperature of the
mutants (Fig. 6d). The plot of the Tm of the mutants
versus their Tagg showed that several of the single
mutations improved the aggregation onset tempera-
ture,without decreasing the thermodynamic stability of
the protein (Fig. 6e). The strongest improvements of
Tagg were obtained with APR suppressing mutations,
where S50K in the light chain and FH101P in the
heavy chain performed best, and their combination is
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Fig. 5. Design of net charge increasing mutation in the
heavy chain. (a) Effect of all mutations on the global
stability (ΔG) and stability of the complex between the
heavy and light chain. Blue: Mutations that were not
selected. Red: Selected mutations. (b) Left: Crystal
structure of mAb2 in complex with VEGF. Gray: mAb2,
green: VEGF. Top right: Zoom on the net charge
increasing mutation SH21R. Red: SH21, blue: RH21.
Bottom right: Zoom on the net charge increasing mutation
SH85R. Red: SH85, blue: RH85. Images were made using
YASARA Structure.
Table 2. mAb2 mutations and their binding properties to
VEGF
VEGF binder Thermophoresis
KD
(nM)
SPR
KD
(nM)
mAb2_WT 3.7 ± 1.1 4.22
mAb2_SL50K 8.3 ± 1.4 7.88
mAb2_SL50D 4.4 ± 1.3 4.68
mAb2_SL52R 3.2 ± 1.8 2.86
mAb2_VH100R NB NB
mAb2_FH101P NB NB
mAb2_SL50K_SH21R_
SH85R
57.1 ± 6.2 –
mAb2_SL50K_FH101P NB –
mAb2_SL50K_SH21R_
SH85R_FH101P
NB –
mAb2_SL52R_FH101P NB –
mAb2_SL52R_SH21R_
SH85R_FH101P
NB –
Bevacizumab (Avastin) 4.8 ± 1.6 ~1.8–20 [33,46]
NB: No binding under assay conditions used.
–: Data not gathered.
Comment: Bevacizumab was used for control experiments. The
obtained binding affinity is in agreement with currently available
published data (KD of ~1.8–20 nM; measured by SPR) [33,46].
1253Aggregation of Monoclonal Antibodiesthe best mutant overall in this plot. The combination of
these two mutations (variant 8 in Fig. 6e) completely
eliminated APR-driven native state aggregation of
mAb2. Variants 8 and 9 of mAb2 display a 15 °C
shift of Tagg, so that Tagg now equals Tm, and their
aggregation is only initiated upon the global unfolding
of the antibody. The net charge increasing mutations
did not cause much further improvement on top of
the effect from the APR (see variants 7 and 9 in
Fig. 6e). Interestingly, the reduction of aggregationpropensity was associated with an increase in the
expression titer of the samemutants (Fig. 6f). Variant 8
had an expression titer that was 4.5-fold higher than
wild-type mAb2, which was 6-fold for variant 9. For
both variants, the net charge increasing mutations
had an additional effect in terms of expression titer.
(Fig. 6f). The improved physicochemical properties
of these Solubis-designed mutants were further
corroborated from the reduced presence of aggre-
gates in the protein stocks as confirmed by dynamic
light scattering and transmission electron microscopy
(Supplementary Figs. 2 and 3). Additionally, size-
exclusion chromatography (SEC) showed an increase
in monomer content, measured immediately after
purification (Supplementary Fig. 4), all indicating that
the improvements are substantial anddetectable using
orthogonal methods.
Overlap with paratope binding requirements
These data demonstrate that critical APRs are a
strong determinant of the aggregation and expression
titer of antibodies, since themutational suppression of
such regions leads to significant improvements of both
properties. However, the overlapping physicochemi-
cal requirements of paratopes and APRs, which are
both enriched in hydrophobic/aromatic residues, will
very likely result in a trade-off between ligand binding
and aggregation propensity. In order to test the ability
of mAb2 variants to still bind their ligand, we
performed surface plasmon resonance (SPR) and
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Table 3. Monomer loss overtime for wild-type and mutant mAb2
Monomer loss overtime m
(per day)
Monomer portion average initial
(t = 0)
Monomer portion average (t = 180 days)
(% area)
mAb2_WT −0.0938 79.10 62.22
mAb2_SL50K SH21R SH85R −0.0179 97.02 93.80
The monomer loss overtime was calculated as slope (m) of the line defined by the monomer content of a sample at the initial and end time
point of the study.
1255Aggregation of Monoclonal Antibodiesmicroscale thermophoresis binding experiments of
wild-type mAb2 and variants thereof with its native
antigen human vascular epithelial growth factor
(Fig. 6g and Table 2). We found that variants
incorporating substitutions in the light chain of mAb2
can still bind human vascular epithelial growth factor
with affinities comparable to wild-type. On the other
hand, the best aggregation-reducing mutation in the
APR of the heavy chain, FH101P, resulted in a
complete loss of antigen binding, which is in line with
the known importance of heavy chain CDR3 for
antigen recognition [37]. Therefore, considering both
ligand binding and aggregation propensity, the most
successful mAb2 variant (Variant 7) has a Solubis
score of 120, exhibits aTagg improvement of 8 °C, and
shows an expression titer increaseofmore than 500%
over the wild-type. The favorable properties of the
mAb2 SL50K_SH21R_SH85R variant were experi-
mentally confirmed by the absence of aggregates in
the stock solution (stored at 4 °C) as observed by
transmission electron microscopy (Supplementary
Fig. 3) and a reduced binding to the rotor dye
Thioflavin-T (Fig. 6h). We also confirmed the improve-
ment of the mAb2 SL50K_SH21R_SH85R variant
with a long-term stability study over a time period of
180 days (Table 3) at 40 °C. The variant shows less
aggregation at t = 0 and a slower decrease of
monomer content overtime when compared to the
wild-type.Discussion
In conclusion, we developed a scoring scheme that
determines the risk for antibody aggregation under
native conditions.Our algorithmconsiders not only the
intrinsic aggregation propensity of the primary anti-Fig. 6. Characterization of mAb2mutants. (a) Far-UV CD sp
FH101P, cyan: VH100R, red: SL52R. (b) Far-UV CD Spectra.
SH21R_SH85R_FH101P, blue: SL50K_FH101P, cyan: SL50K
(c) Intrinsic fluorescence emission spectra upon excitation at
dependent evolution of the RALS intensity for wild-type and
temperatures of wild-type and mutants at 1 mg/mL, obtained
titers for mAb2 wild-type and mutants. (g) VEGF binding det
mAb2 WT and selected mutants. (h) Fluorescence intensity of
the mutants SL50K_SH21R_SH85R and FH101P_SL50K_S
recorded at 480 nm. (i) Correlation between the Solubis score
for mAb2 wild-type and mutant; numbers are indicated.body sequences but also the structural context in
which these aggregation-prone sequences are em-
bedded. Thus, starting from the full set of APRs in an
antibody's primary sequence, the scoring function
identifies those that most likely actually trigger
aggregation in the fully folded protein under native
conditions. In our test set of 11 antibodies, the total
number of APRs in the primary sequence of the
different antibodies ranges between 4 and 10 APRs.
However, only in a fully unfolded and extended state
of a polypeptide will all these APRs be available for
aggregation.
In antibodies, just as in any globular protein, most
APRs will be buried in the hydrophobic core of the
protein where they will contribute to thermodynami-
cally stabilizing tertiary interactions of the protein. This
also means that these APRs are thereby protected
from aggregation by their engagement in native
interactions. The more stable these interactions, the
more efficient this protection. Our algorithm therefore
filtersAPRsby their contribution to the thermodynamic
stability of the native protein. In our test set of 11
antibodies, this filtering lowers the amount of relevant
APRs to zero, one, or two APRs per antibody
(i.e., critical APRs). Based on these critical APRs
only, the scheme allows us to correctly classify the
antibodies in this limited set into antibodies that are at
risk of aggregating in their native conformation and
antibodies that are only at risk of aggregation when
they globally denature (e.g., melt upon heating). Of
course, given the canonical structure of antibodies,
critical APRs, in their vast majority, will be part of
CDRs. To demonstrate that the critical APRs predict-
ed by our method are indeed responsible for native
state aggregation, we reengineered the aggregation-
prone antibody 2, which resulted in mutants with
reduced native aggregation without abrogatingectra. Black: Wild-type, yellow: SL50K, green: SL50D, blue:
Black: Wild-type, yellow: SL52R_FH101P, green: SL52R_
_SH21R_SH85R_FH101P, red: SL50K_SH21R_SH85R.
20 °C of mAb2 and indicated mutants. (d) Temperature-
two mutants. (e) Aggregation onset points and melting
from transiently transfected CHO K1 cells. (f) Expression
ermination using optical laser-induced thermophoresis of
the rotor dye Thioflavin-T in the presence of mAb2 WT and
H21R_SH85R. Excitation was at 440 nm, emission was
and the difference between the Tm and the Tagg (ΔTmTagg)
1256 Aggregation of Monoclonal Antibodiesepitope binding. Interestingly, we found that these
same mutations also improve the expression titer of
the antibody up to more than 4.5-fold for the best
variants. These results demonstrate the importance of
β-aggregation for the chemistry, manufacturing, and
control properties of monoclonal antibodies and the
importance of identifying critical APRs within CDRs.
The overlap between epitope binding and the
aggregation potential of antibodies is a critical point.
Indeed, as discussed above, APRs occurring in
constant regions of the protein are typically buried in
the hydrophobic core of one of the immunoglobulin
domains and therefore contribute little to native state
aggregation propensity. Therefore, a simple proxy
for our scoring scheme could be to use the TANGO
score of the CDRs to evaluate the aggregation
propensity of antibodies, and indeed, in our test set,
this would work reasonably well: only mAb4 would
be wrongly classified as aggregation-prone. This
antibody has a strong APR in CDR loop 3 of the
light chain, but since this loop is stably integrated
into the fold of this antibody, the presence of the
loop does not result in a strong aggregation
propensity under native conditions. Thus, although
a larger dataset would be required to determine
which method is more accurate, our data suggest
that consideration of the full structural context will
be more specific.
One could also argue that the overall TANGOscore,
unmitigated by the structural context, is a simpler
method than the Solubis score in classifying the
antibodies.With this approach, the presence of critical
APRs in problematic antibodies then simply adds up
on top of the sum of identical APRs in the constant or
highly similar framework sequences and thus tends to
correlate with a higher overall TANGO score. In
classifying aggregation-prone antibodies, the Solubis
score clearly outperforms the overall TANGO score
for thewild-type antibodies (Fig. 3g andTable 4). Also,
it is interesting to notice that there is not much
predictive power in the number of APRs in an
antibody, where the number of critical APRs is a
powerful method. When looking whether the Solubis
score correlates with the Tm‐Tagg gap for mAb2 wild-
type and mutants, we can see a clear trend, but
mutant FH101P has a larger effect on the Tm‐Tagg
gap than would be expected from the Solubis score
(Fig. 6i and Table 4). Additionally, mutant SL50D has
a substantial effect on the Solubis score but did not
affect the Tm‐Tagg gap. Interestingly, this is the one
mutation that reduces the net charge compared to
wild-type, suggesting that this factor might need to be
incorporated into future improvements to our scoring
scheme. Although our dataset is perhaps too small to
identify the best scoring scheme, it is clear that the
method of identifying critical APRs achieves the best
prediction power on the current set and, at the same
time, identifies the sites where the protein might
benefit from engineering.After analyzing over 2000 antibody structures, we
find that a substantial fraction of these possess
CDRs with critical aggregation propensity. Indeed,
epitope binding imposes specific sequence require-
ments on paratopes such as a bias toward aromatic
sequences, which will also favor aggregation.
Contrary to APRs in the core of the immunoglobulin
fold, APRs in CDRs are not selected for structure but
for binding. As a result, these APRs are generally not
significantly contributing to the thermodynamic sta-
bility of the protein and therefore promote aggrega-
tion even when the antibody is properly folded.
Comparing the aggregation propensity of FDA-
approved antibodies with the abYsis set of over 2000
antibodies clearly shows that CDRs with extreme
Solubis scores do not possess the requirements
allowing commercial exploitation. Interestingly,
about 15% of FDA-approved antibodies analyzed
here still possess at least one critical APR. This
indicates that antibody formulation is an efficient
method to stabilize monoclonal antibodies that may
act in part by helping shield the critical APRs from
aggregation. However, our results also suggest that
identifying critical APRs can further support candi-
date selection of antibodies in the context of quality
by design and risk management in development.Materials and Methods
Database retrieval
The abYsis database [24] was queried with the
PDB as data source, all organisms, excluding
sequences with warnings and excluding unclassi-
fied, unpaired, and unnumbered sequences. This
resulted in 2561 antibody structures. Duplicates
were removed and also antibodies that contained
errors after downloading, resulting in a database of
2104 antibody structures. Redundancy was re-
moved using the CD-HIT webserver using sequence
identity cutoffs of 0.95 and 0.90 [42].
The WHATIF culled dataset with representative
PDB structures of globular proteins was obtained
from http://swift.cmbi.ru.nl/gv/select/. Dataset
was culled at 30% sequence identity for structures
with an R-factor of b0.20 and a resolution of
b2.5 Å [25].
Selection of 11 publicly available antibodies
from the abYsis database
All human sequences available in the abYsis
database were acquired, and properties like charge
distribution, hydrophobicity, statistical sequence
scores [29], CDR-specific properties, and aggrega-
tion tendency (PASTA [30]) were computed. For
each of these properties, a distribution was obtained
Table 4. Summary of antibodies used for scoring function
validation
Antibody TANGO Solubis
Score
Class No. of
APRs
Mutant
mAb2 1908 377 1 8 No
mAb3 1131 71 0 7 No
mAb4 1621 51 0 6 No
mAb5 2269 321 1 10 No
mAb7 2042 681 1 7 No
mAb8 1639 50 0 7 No
mAb9 680 93 1 5 No
mAb10 695 71 0 5 No
mAb11 771 4 0 3 No
mAb2 VH100R 1652 268 1 8 Yes
mAb2 FH101P 1653 279 0 8 Yes
mAb2 SL50D 1256 125 1 7 Yes
mAb2 SL50K 1228 119 1 7 Yes
mAb2 SL50K SH21R
SH85R
1228 119 1 7 Yes
mAb2 SL52R 1246 127 1 7 Yes
mAb2 FH101P SL50K 972 30 0 7 Yes
mAb2 FH101P SL50K
SH21R SH85R
972 30 0 7 Yes
mAb2 FH101P SL52R 991 30 0 7 Yes
mAb2 FH101P SL52R
SH21R SH85R
990 30 0 7 Yes
1257Aggregation of Monoclonal Antibodiesand antibodies were selected that were extreme in at
least one property and had an X-ray structure
available. Exceptions were mAb5, which scored
average in all distributions, and mAb9 and mAb10,
which were randomly selected and for which no
X-ray structure was available.
Homology modeling
Homology modeling was performed using the
“Antibody Modeler” application of MOE 2015.10
(Chemical Computing Group Inc., Montreal, Canada).
The application was run fully automated according to
the procedures described in the manual. However,
templates that correspond to the available crystal
structure of the test mAb were excluded. Side-chain
clashing energy cutoff was set to 1.5 kcal/mol, inter-
mediates were refined with the “medium” setting, and
final models were refined with the “fine” setting. GB/VI
scoring was employed, and energyminimizations were
performed with the Amber10:EHT (R-Field) force field.
In a further approach, an additional energy minimi-
zation step was performed subsequent to the homol-
ogy modeling (force field: Amber10:EHT; R-Field
1:80; Cutoff (8.10) ; root mean square gradient of
0.1 kcal/mol/A2).
Homology modeling with YASARA was performed
using the homology modeling macro supplied with
YASARAStructure (hm_build.mcr). Standard settings
were used, and only the FASTA sequence of the
heterodimer of the Fv-domain of each mAb was
provided.In silico analysis
The following method was used for each antibody
structure analyzed. APRs were identified using
TANGO [19] at default settings, and the location was
defined using the Chothia canonical numbering
scheme [38]. All structures were cleaned and pre-
pared for analysis using YASARA Structure [39], after
which they were repaired using the FoldX force field
[18]. The SequenceDetail command was run with
FoldX for all repaired structures. Python scripting was
used to retrieve the summedΔG of eachAPR from the
SequenceDetail files. R-Studio [40] was used tomake
Stretch-plots using the plot function and density plots
using the stat_density2d function, both from the
ggplot2 package [46]. The summed ΔG value was
cut off between −5 and 5 kcal/mol. This value was
scaled between 0 and 1, after which it was used to
scale all TANGO scores with this value, giving APRs
with summed ΔG values of −5 and lower a score of 0.
For each antibody, all APR scores were summed,
resulting in the score defined by the scoring function.
Protein production and purification
Variable regions of mAb candidates were synthe-
sized and inserts cloned into expression vectors
already containing constant regions of an IgG1 isotype.
Heavy Chain (HC) and Light Chain (LC) were cloned
into individual expression vectors and co-transfected.
Wild-type mAbs were produced in stable clones of
CHO DG44 cells in a 10-day fed-batch culture in
CD-OptiCHOwith a 10% bolus feed on day 3 and day
6 using CD EfficientFeed C (Life Technologies) [41].
mAb2 variants were produced by transient expres-
sion in CHO K1 suspension adapted cells. The seeds
were grown in an optimized, chemically defined,
animal-component free, and serum-free media. Cells
were transfected with a proprietary transfection agent.
After transfection, cells were grown in an optimized
mediawith proprietary recipe at 37 °Cand5%CO2 for
8 days.
The proteins were purified from cell culture superna-
tant via protein A affinity chromatography (MabSelect
or rProtein A Sepharose, GE Healthcare). The purified
mAbs were analyzed by reducing and non-reducing
SDS-PAGE. Quantification of mAb aggregation/
fragmentation was performed by SEC.
Production mAb2 variants
Variable regions of mAb candidates were synthe-
sized and inserts cloned into a pTT5 expression vector
(CNRC-NRC) already containing constant regions of
an IgG1 isotype.HCandLCwere cloned into individual
expression vectors. CHO 3E7 cells (CNRC-NRC
[42,43]) were cultivated in shake flasks usingFreeStyle
CHO medium (Life Techologies) + 2 mM L-Gln. HC
andLCexpression vectorswere co-transfected in a 1:1
1258 Aggregation of Monoclonal Antibodiesplasmid ratio into CHO 3E7 cells with a DNA-to-PEIpro
(Polyplus) ratio of 1:6. Each mAb variant was
transfected in triplicates. Subsequently, cells were
cultured for 8 days in shake flasks on an orbital shaker
(Infors) set to 120 rpm, with 5% CO2 and 32 °C, using
FreeStyle CHO medium (Life Techologies) + 2 mM
L-Gln without selection pressure. At 24 h post-
transfection, cells were supplemented with HyClone
Cell Boost 5 (Thermo Scientific). The concentration of
secreted IgG in the harvested culture media was
determined on day 8 post-transfection with an Octet
QKe (ForteBio) using Protein A biosensors.
Target binding determination using optical
laser-induced thermophoresis
The method description and experimental perfor-
mance was described previously [44,45]. Briefly,
recombinant human VEGFa (UniProt ID P15692;
aa 27–191) was fluorescently labeled with Alexa-647.
Target binding affinities were determined in solution
using labeled recombinant human Vascular Endothe-
lial Growth Factor a (rhVEGFa) at a constant concen-
tration of 1 nM, whereas mAb2 WT or variants thereof
were added in varying concentrations. All measure-
ments were performed in triplicates at 295 K, 20%LED
power, and 20% IR- laser power. Laser-on and -off
times were adjusted to 30 s and 5 s, respectively. All
experiments were carried out in 25 mM sodium citrate
buffer at pH 6.0 containing 125 mM sodium chloride
and 0.05% Tween 20. Bevacizumab (Avastin®,
Genentech, Inc.) was used for control experiments.
All measurements were conducted on a NanoTemper
Monolith NT.115 instrument. Datawere analyzed using
the NanoTemper Analysis version 1.5.41 (NanoTem-
per Technologies GmbH).
Determination of melting point (Tm) and
aggregation onset temperatures (Tagg)
Tm and Tagg of all antibodies were determined by
intrinsic tryptophan fluorescence using the OPTIM
1000 (Avacta Analytical Ltd., York, UK) instrument.
All experiments were performed in triplicates of
triplicates. The analysis of all antibodies was done at
a concentration of 0.7 mg/mL in 25 mM Na-Citrate
and 125 mM NaCl (pH 6.0). mAb2 WT and variants
were analyzed at a concentration of 1 mg/mL in
25 mM Na-Citrate and 125 mM NaCl (pH 6.0). For
all experiments, a temperature ramp was performed
from 15 to 95 °C, with an increase of 0.3 °C/min.
Exposure time was set to 2000 milliseconds. Melting
temperatures and aggregation onset temperatures
were determined with the instrument software.
CD
A J-1500-150ST (Jasco) CD Spectrometer with a
peltier temperature control system was used tocollect CD spectra. All measurements were collected
at 25 °C between 190 and 260 nm with a pitch of
1 nm at a scan speed of 50 nm min–1, a response
time of 4 s, slit widths of 2 nm, and standard
sensitivity.
Long-term storage stability/SEC
An accelerated aggregation study of mAb2WT and
the variant mAb2_SL50K_SH21R_SH85R was per-
formed. Samples of 5 mg/mL in 25 mM sodium citrate
and 125 mMsodiumchloride (pH 6.0)were incubated
at 40 °C over a time span of 6 months (180 days). The
unstressed samples (t = 0) were analyzed immedi-
ately after preparation. All 40 °C incubated samples
were stored at −70 °C and analyzed together at the
end of the study. The amounts of aggregation and
remainingmonomer content were determined bySEC
on an Alliance HPLC system (Waters, Milford, MA,
USA) employing a TSKgel G3000 SWX column
(Tosoh Bioscience LLC). The monomer loss overtime
was calculated as slope (m) of the line defined by the
monomer content of a sample at the initial and end
time point of the study.
The mobile phase was 50 mM Tris/HCl and
150 mM sodium chloride buffer (pH 7.5) at a flow
rate of 1 mL/min. Areas of peaks followed by 280 nm
are integrated at each time point. All samples were
measured in duplicates.
Electron microscopy
We deposited 10 μL of the samples (1 mg/ml) on
glow-discharged, carbon-coated 400 mesh copper
grids for 1 min. Subsequently, the grids were
washed briefly 5× on drops of MilliQ filtered H2O
and stained for 1 min with 1% filtered uranyl
acetate. After blotting and drying, the grids were
observed in a JEOL JEM1400 transmission elec-
tron microscope equipped with an Olympus SIS
Quemesa 11 Mpxl camera at an acceleration
voltage of 80 kV.
SPR
The affinity of mAb2 WT and mutants was
determined by SPR using a Biacore 3000 analytical
system (GE Healthcare, Uppsala, Sweden). mVEGF
was covalently coupled (890RU) to a CM5 sensor
chip [using a concentration of 2 μg/mL mVEGF in
acetate buffer of 10 mmol/L (pH 4.5)]. mAb2 variants
(diluted in HBS-EP buffer to concentrations between
10 and 200 nM) were injected at a flow rate of 30 μL/
min, followed by a dissociation. After each cycle, the
sensor chip was regenerated using glycine
[10 mmol/L (pH 1.5)]. The association and dissoci-
ation rate constants were determined using the
BIAcore 3000 evaluation software (Langmuir bind-
ing, global fit).
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